Sage Therapeutics (NASDAQ:SAGE) Given New $18.00 Price Target at Truist Financial
Sage Therapeutics (NASDAQ:SAGE – Free Report) had its price target reduced by Truist Financial from $22.00 to $18.00 in a research note published on Friday, Benzinga reports. They currently have a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on SAGE. Scotiabank decreased their price objective […]